Illumina
As on 23 May, 2025 | 01:29 IST
| Open | 79.23 |
| Previous Close | 79.37 |
| Beta | 0.60 |
| High | 80.66 |
| Low | 79.00 |
| TTM EPS See historical trend | 3.33(+278.41% YoY) |
| 52 Week High | 156.55 |
| 52 Week Low | 68.70 |
| TTM PE See historical trend | 24.19(Low PE) |
| Mkt. Cap ($ Billion) | 12.80 |
| Dividend Yield | -- |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 82.13 |
| 10 | 80.75 |
| 20 | 79.01 |
| 50 | 79.36 |
| 100 | 99.06 |
| 200 | 117.53 |
Returns
| 1 Week | -0.54% | |
| 1 Month | 8.37% | |
| 3 Months | -14.51% | |
| YTD | -39.60% | |
| 1 Year | -24.94% | |
| 3 Years | -66.92% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 490.04 | 0.39 | 189.13 | 23.04 | 21.27 | 0.27 | 491.52/0.00 | -7.96 | Bearish |
| Intuitive Surgical | 473.86 | 0.58 | 166.83 | 88.74 | 5.34 | -- | 475.60/0.00 | -20.52 | Neutral |
| Boston Scientific | 105.70 | -0.16 | 154.85 | 53.12 | 1.99 | -- | 107.00/0.00 | -0.47 | Bearish |
| Danaher | 205.36 | 0.18 | 151.75 | 22.08 | 9.30 | 0.45 | 207.39/0.00 | -0.63 | Bearish |
| Edwards Lifesciences | 81.23 | 0.41 | 49.27 | 32.36 | 2.51 | -- | 81.69/0.00 | 6.57 | Bearish |
Market news
- S&P 500 ends lower as Dell and Nvidia dropAugust 30, 2025 10:46 AM
- Dow notches record high as Wall Street cheers Powell's speechAugust 23, 2025 10:31 AM
- Dow ends higher after UnitedHealth gains, other indexes slip on rate cut uncertaintyAugust 16, 2025 11:08 AM
- Stocks slump on latest tariffs, soft jobs dataAugust 2, 2025 11:55 AM
About the company
Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions. The Company operates through segments such as Core Illumina. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina consists of its core operations. The Company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.